NCT06155422

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 670 (estimated)
• Sponsor: Gang Chen (101199) · Academic / Other
• Sex: Female
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.

Conditions

• Recurrent or Metastatic Cervical Cancer

Interventions

Type	Name	Description
DRUG	Cadonilimab	recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment

Timeline

• Start date: 2023-11-30
• Primary completion: 2026-11-30
• Completion: 2027-11-30
• First posted: 2023-12-04
• Last updated: 2023-12-04